Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Clinical trial NCT07609121 · RECRUITING

Trial details

NCT number: NCT07609121
Sponsor: Sun Yat-sen University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)

Start date: 2026-06-01
Primary completion: 2029-05-31
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.